Document Detail

Cancer procoagulant in patients with adenocarcinomas.
MedLine Citation:
PMID:  16269926     Owner:  NLM     Status:  MEDLINE    
Cancer procoagulant (CP) is a cysteine proteinase that may be produced by malignant and foetal tissue. The possible role of CP in the pathogenesis of cancer-related thrombosis has been suggested recently. The purpose of the study was to evaluate coagulation prothrombotic markers and their relation to CP concentration in the blood of patients with gastrointestinal adenocarcinomas (GIAC). The study group consisted of 45 patients with confirmed diagnosis of adenocarcinoma (stomach, 18 patients; colon, 27 patients) and without evident metastatic disease. In 24 patients further observation showed metastases. The control group for CP was composed of 10 healthy subjects. Blood samples were drawn on the admission day, before any treatment. Among 45 patients with GIAC, deep venous thrombosis was observed in two (4.4%). In all patients the CP activity in the serum was found, and the mean CP activity shortened the coagulation time almost three times compared with the healthy control group. Also, the mean thrombin-antithrombin complex concentration was above the normal range. A significant elevation of the mean prothrombin fragment 1+2 plasma content in this group of patients was noticed. Despite these observations, CP remained within the normal range and did not correlate with thrombin-antithrombin complex or prothrombin fragment 1+2 plasma concentrations. A positive correlation was observed between serum CP and fibrinogen concentration, and a negative correlation between CP and free protein S plasma content (P = 0.04 and P = 0.025, respectively). A negative correlation between activated protein C resistance ratio and protein C activity in the plasma was confirmed. Protein C activity in the plasma showed a correlation with free protein S plasma content. Analysis of factors influencing the activated partial thromboplastin time revealed the presence of antiphospholipid antibodies in seven persons from the study group (in three cases of IgG and in four cases of IgM class). Our data suggest that CP is a minor risk factor for deep venous thrombosis in GIAC patients. To confirm this, however, the number of patients and controls should be larger. After 3 years of observation, the follow-up in 10 living GIAC patients showed nobody with thromboembolic disease.
Maciej Kaźmierczak; Krzysztof Lewandowski; Marek Z Wojtukiewicz; Zofia Turowiecka; Edyta Kołacz; Anna Lojko; Elzbieta Skrzydlewska; Krystyna Zawilska; Mieczysław Komarnicki
Related Documents :
12410646 - First-time development of fviii inhibitor in haemophilia patients during the postoperat...
22608296 - Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillo...
14962206 - Treatment of acquired haemophilia with factor eight inhibitor bypassing activity.
8323396 - Baseline plasma fibrinolysis and its correlation with clinical manifestations in patien...
1319696 - 99mtechnetium-labelled red blood cell scintigraphy as an alternative to angiography in ...
9326656 - Developmental disorder associated with increased cellular nucleotidase activity.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  16     ISSN:  0957-5235     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-04     Completed Date:  2006-01-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  543-7     Citation Subset:  IM    
Department of Haematology, University of Medical Sciences, Poznań, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / blood*,  complications
Biological Markers / blood
Blood Proteins / analysis
Colonic Neoplasms / blood*,  complications
Cysteine Endopeptidases / blood*
Middle Aged
Neoplasm Proteins / blood*
Partial Thromboplastin Time
Predictive Value of Tests
Risk Factors
Stomach Neoplasms / blood*,  complications
Venous Thrombosis / blood*,  etiology
Reg. No./Substance:
0/Biological Markers; 0/Blood Proteins; 0/Neoplasm Proteins; EC 3.4.22.-/Cysteine Endopeptidases; EC procoagulant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Back to the future: testing in disseminated intravascular coagulation.
Next Document:  Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII...